Join our daily newsletter At The Bell to receive exclusive market insights
- Aeris Environmental (AEI) has had its Aeris Active sanitiser further validated against COVID-19 by a Sydney-based testing lab
- The product has been proven to have a 99.99 per cent kill efficiency after just 60 seconds in contact with a virus
- However, the product was never strictly tested against COVID-19
- Rather, Aeris Active was tested against a surrogate virus, which is part of the coronavirus family
- Still, Aeris insists this virus is often used as a substitute for COVID-19 in published disinfectant studies
- Investors were happy with today’s news either way, as Aeris shares soared over 60 per cent to trade for 63 cents each at lunchtime
Aeris Environmental (AEI) has had its Aeris Active sanitiser product validated by a Sydney-based biopharma product-testing group.
Eurofins AMS Laboratories has tested Aeris Active and told the company the sanitiser can kill coronaviruses in just 60 seconds.
However, the product was not strictly tested against the COVID-19 strain of coronavirus which is currently wreaking havoc across the globe.
Rather, Aeris Active was tested against Murine hepatitis virus, also known as ATCC VR-261. This virus is part of the coronavirus family and, according to Aeris, has been used as a surrogate for COVID-19 in published disinfectant studies.
In the Aeris Active test, the product was found to kill 99.99 per cent of the virus after just 60 seconds of contact, providing the rapid deterioration of the virus.
While Aeris Active was originally developed as a mould and mildew killer, the product thrust the company into the spotlight in February when it made the Singapore National Environmental Agency’s list of disinfectants effective against COVID-19.
The product piqued the interest of health professionals and investors alike because of its “residual protection” capabilities. Aeris Active not only kills a range of viruses, bacteria, and fungi but leaves behind a residue that can keep a surface safe for 200 touches or seven days.
As such, the company has seen unprecedented demand for the product across the globe and particularly in Asian markets.
In response, Aeris said it is scaling up supply and now has several manufacturing sites in production.
Despite today’s announcement making no mention of Aeris Active being directly tested against Covid-19, investors seem thrilled with the efficacy against the surrogate virus.
Aeris Environmental is topping the gainers’ list today, with shares up a whopping 61.54 per cent at lunchtime AEDT. Shares are currently trading for 63 cents each.
